Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Sells $249,951.00 in Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) insider Jing L. Marantz sold 5,655 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $44.20, for a total transaction of $249,951.00. Following the sale, the insider now owns 67,200 shares in the company, valued at $2,970,240. The trade was a 7.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Scholar Rock Price Performance

Shares of NASDAQ:SRRK opened at $45.40 on Friday. The company’s fifty day moving average price is $40.69 and its 200-day moving average price is $23.90. The firm has a market capitalization of $4.25 billion, a price-to-earnings ratio of -19.32 and a beta of 0.52. Scholar Rock Holding Co. has a one year low of $6.76 and a one year high of $46.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on SRRK. JPMorgan Chase & Co. upped their price target on shares of Scholar Rock from $18.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, October 14th. Wedbush restated an “outperform” rating and set a $47.00 price target on shares of Scholar Rock in a research note on Thursday, January 9th. Piper Sandler upped their price target on shares of Scholar Rock from $28.00 to $42.00 and gave the company an “overweight” rating in a research note on Tuesday, October 15th. Truist Financial upped their target price on shares of Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, November 25th. Finally, BMO Capital Markets upped their target price on shares of Scholar Rock from $34.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, October 11th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $40.43.

Hedge Funds Weigh In On Scholar Rock

A number of institutional investors have recently made changes to their positions in SRRK. Clearbridge Investments LLC bought a new position in shares of Scholar Rock in the 2nd quarter worth $6,223,000. Fisher Asset Management LLC increased its holdings in shares of Scholar Rock by 593.6% in the 3rd quarter. Fisher Asset Management LLC now owns 734,019 shares of the company’s stock worth $5,879,000 after buying an additional 628,186 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Scholar Rock by 159.2% in the 2nd quarter. Millennium Management LLC now owns 925,584 shares of the company’s stock worth $7,710,000 after buying an additional 568,512 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Scholar Rock by 1,051.3% in the 2nd quarter. Marshall Wace LLP now owns 487,285 shares of the company’s stock worth $4,059,000 after buying an additional 444,961 shares during the last quarter. Finally, FMR LLC increased its holdings in shares of Scholar Rock by 3.1% in the 3rd quarter. FMR LLC now owns 10,196,046 shares of the company’s stock worth $81,670,000 after buying an additional 308,813 shares during the last quarter. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.